Interleukin-7 immunotherapy

Claude Sportès, Ronald E. Gress

Research output: Chapter in Book/Report/Conference proceedingConference contribution

23 Scopus citations


IL-7 is a member of the common γ -chain family of cytokines sharing a common γ -chain in their receptor. Beyond its long-established pivotal role in immune development, it has been more recently recognized as a critically important regulator of peripheral naïve and memory T cell homeostasis while its role in postdevelopment thymic function remains at best, poorly defined, and controversial. Its multiple immune-enhancing properties, most notably in the maintenance of T cell homeostasis, make it a very attractive candidate for immunotherapy in a wide variety of clinical situations. Following many years of rich preclinical data in murine and simian models, IL-7 is now emerging in human phase I trials as a very promising immunotherapeutic agent. Human in vivo data discussed here are derived from the phase I study initiated at the National Cancer Institute in collaboration with Cytheris, Inc., in a cohort of subjects with incurable malignancy.

Original languageEnglish (US)
Title of host publicationImmune-Mediated Diseases
Subtitle of host publicationFrom Theory to Therapy
EditorsMichael Shurin, Yuri Smolkin
Number of pages13
StatePublished - 2007
Externally publishedYes

Publication series

NameAdvances in Experimental Medicine and Biology
ISSN (Print)0065-2598

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'Interleukin-7 immunotherapy'. Together they form a unique fingerprint.

Cite this